A general and islet cell-enriched overexpression of IGF-I results in normal islet cell growth, hypoglycemia, and significant resistance to experimental diabetes

American Journal of Physiology - Endocrinology and Metabolism

Volumn 294, Issue 5, 2008, Pages

  Robertson, Katie ^a   Lu, Yarong ^a   De Jesus, Kristine ^a   Li, Bing ^a   Su, Qing ^a   Lund, P Kay ^b   Liu, Jun Li ^a,c,d  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c Montreal Diabetes Research Centre   (Canada)

^d ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

Gluconeogenesis; Insulin like growth factor I; Metallothionein promoter; Pancreatic islets; Streptozotocin

Indexed keywords

METALLOTHIONEIN I; PYRUVIC ACID; SOMATOMEDIN C; STREPTOZOCIN; INSULIN; METALLOTHIONEIN; PYRUVIC ACID DERIVATIVE; RNA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BODY GROWTH; CELL GROWTH; CELL SURVIVAL; DEATH; EXPERIMENTAL DIABETES MELLITUS; FEMALE; GENE; GENE OVEREXPRESSION; GENE TARGETING; GLUCONEOGENESIS; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; HYPOGLYCEMIA; HYPOINSULINEMIA; IGF I GENE; INSULIN RELEASE; INSULIN SENSITIVITY; MALE; MOUSE; NONHUMAN; PANCREAS; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL; PRIORITY JOURNAL; PROVOCATION TEST; PYRUVATE TOLERANCE TEST; RECEPTOR GENE; WEIGHT REDUCTION; ANIMAL; BIOSYNTHESIS; BLOOD; CELL PROLIFERATION; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; GLUCOSE TOLERANCE TEST; HUMAN; IMMUNOHISTOCHEMISTRY; INSULIN RESISTANCE; ISOLATION AND PURIFICATION; METABOLISM; NORTHERN BLOTTING; PANCREAS ISLET; PATHOLOGY; PHYSIOLOGY; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSGENIC MOUSE;

ANIMALS; BLOTTING, NORTHERN; CELL PROLIFERATION; DIABETES MELLITUS, EXPERIMENTAL; FLUORESCENT ANTIBODY TECHNIQUE; GLUCONEOGENESIS; GLUCOSE TOLERANCE TEST; HUMANS; HYPOGLYCEMIA; IMMUNOHISTOCHEMISTRY; INSULIN; INSULIN RESISTANCE; INSULIN-LIKE GROWTH FACTOR I; ISLETS OF LANGERHANS; METALLOTHIONEIN; MICE; MICE, TRANSGENIC; PYRUVATES; RATS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA;

EID: 45549108397     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00606.2007     Document Type: Article

References (62)

1. Acerini CL, Patton CM, Savage MO, Kernell A, Westphal O, Dunger DB. Randomised placebo-controlled trial of human recombinant insulin-like growth factor I plus intensive insulin therapy in adolescents with insulin-dependent diabetes mellitus. Lancet 350: 1199-1204, 1997.
2. Adams GA, Wang X, Lee LK, Piercy CE, Alfrey EJ, Dafoe DC. Insulin-like growth factor-I promotes successful fetal pancreas transplantation in the intramuscular site. Surgery 116: 751-755; discussion 756-757, 1994.
3. Altomonte J, Richter A, Harbaran S, Suriawinata J, Nakae J, Thung SN, Meseck M, Accili D, Dong H. Inhibition of Foxo1 function is associated with improved fasting glycemia in diabetic mice. Am J Physiol Endocrinol Metab 285: E718-E728, 2003.
4. Amacker-Françoys I, Mohanty S, Niessen M, Spinas GA, Trüb T. The metabolisable hexoses D-glucose and D-mannose enhance the expression of IRS-2 but not of IRS-1 in pancreatic beta-Cells. Exp Clin Endocrinol Diabetes 113: 423-429, 2005.
5. Behringer RR, Lewin TM, Quaife CJ, Palmiter RD, Brinster RL, D'Ercole AJ. Expression of insulin-like growth factor I stimulates normal somatic growth in growth hormone-deficient transgenic mice. Endocrinology 127: 1033-1040, 1990.
6. Bergerot I, Fabien N, Maguer V, Thivolet C. Insulin-like growth factor-1 (IGF-1) protects NOD mice from insulitis and diabetes. Clin Exp Immunol 102: 335-340, 1995.
7. Camacho-Hubner C, Clemmons DR, D'Ercole AJ. Regulation of insulin-like growth factor (IGF) binding proteins in transgenic mice with altered expression of growth hormone and IGF-I. Endocrinology 129: 1201-1206, 1991.
8. Carroll PV, Umpleby M, Ward GS, Imuere S, Alexander E, Dunger D, Sonksen PH, Russell-Jones DL. rhIGF-I administration reduces insulin requirements, decreases growth hormone secretion, and improves the lipid profile in adults with IDDM. Diabetes 46: 1453-1458, 1997.
9. Carson MJ, Behringer RR, Brinster RL, McMorris FA. Insulin-like growth factor-I increases brain growth and central-nervous-system myelination in transgenic mice. Neuron 10: 729-740, 1993.
10. Casellas A, Salavert A, Agudo J, Ayuso E, Jimenez V, Moya M, Munoz S, Franckhauser S, Bosch F. Expression of IGF-I in pancreatic islets prevents lymphocytic infiltration and protects mice from type 1 diabetes. Diabetes 55: 3246-3255, 2006.
11. Chen W, Salojin KV, Mi QS, Grattan M, Meagher TC, Zucker P, Delovitch TL. Insulin-like growth factor (IGF)-I/IGF-binding protein-3 complex: therapeutic efficacy and mechanism of protection against type 1 diabetes. Endocrinology 145: 627-638, 2004.
12. Chernausek SD, Backeljauw PF, Frane J, Kuntze J, Underwood LE, and for the GHISCG. Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity. J Clin Endocrinol Metab 92: 902-910, 2007.
13. Clemmons DR, Moses AC, McKay MJ, Sommer A, Rosen DM, Ruckle J. The combination of insulin-like growth factor I and insulin-like growth factor-binding protein-3 reduces nsulin requirements in insulin-dependent type 1 diabetes: evidence for in vivo biological activity. J Clin Endocrinol Metab 85: 1518-1524, 2000.
14. Di Cola G, Cool MH, Accili D. Hypoglycemic effect of insulin-like growth factor-1 in mice lacking insulin receptors. J Clin Invest 99: 2538-2544, 1997.
15. Dickson LM, Rhodes CJ. Pancreatic β-cell growth and survival in the onset of type 2 diabetes: a role for protein kinase B in the Akt? Am J Physiol Endocrinol Metab 287: E192-E198, 2004.
16. Fryburg DA, Jahn LA, Hill SA, Oliveras DM, Barrett EJ. Insulin and insulin-like growth factor-I enhance human skeletal muscle protein anabolism during hyperaminoacidemia by different mechanisms. J Clin Invest 96: 1722-1729, 1995.
17. George M, Ayuso E, Casellas A, Costa C, Devedjian JC, Bosch F. beta cell expression of IGF-I leads to recovery from type 1 diabetes. J Clin Invest 109: 1153-1163, 2002.
18. Giannoukakis N, Mi Z, Rudert WA, Gambotto A, Trucco M, Robbins P. Prevention of beta cell dysfunction and apoptosis activation in human islets by adenoviral gene transfer of the insulin-like growth factor I. Gene Ther 7: 2015-2022, 2000.
19. Guo Y, Lu Y, Houle D, Robertson K, Tang Z, Kopchick JJ, Liu YL, Liu JL. Pancreatic islet-specific expression of an IGF-I transgene compensates islet cell growth in growth hormone receptor gene deficient mice. Endocrinology 146: 2602-2609, 2005.
20. Hennige AM, Burks DJ, Ozcan U, Kulkarni RN, Ye J, Park S, Schubert M, Fisher TL, Dow MA, Leshan R, Zakaria M, Mossa-Basha M, White MF. Upregulation of insulin receptor substrate-2 in pancreatic beta cells prevents diabetes. J Clin Invest 112: 1521-1532, 2003.
21. Hill DJ, Petrik J, Arany E, McDonald TJ, Delovitch TL. Insulin-like growth factors prevent cytokine-mediated cell death in isolated islets of Langerhans from pre-diabetic non-obese diabetic mice. J Endocrinol 161: 153-165, 1999.
22. Holst LS, Mulder H, Manganiello V, Sundler F, Ahren B, Holm C, Degerman E. Protein kinase B is expressed in pancreatic beta cells and activated upon stimulation with insulin-like growth factor I. Biochem Biophys Res Commun 250: 181-186, 1998.
23. Hugl SR, White MF, Rhodes CJ. Insulin-like growth factor I (IGF-I)-stimulated pancreatic beta-cell growth is glucose-dependent. Synergistic activation of insulin receptor substrate-mediated signal transduction pathways by glucose and IGF-I in INS-1 cells. J Biol Chem 273: 17771-17779, 1998.
24. Kaino Y, Hirai H, Ito T, Kida K. Insulin-like growth factor I (IGF-I) delays the onset of diabetes in non-obese diabetic (NOD) mice. Diabetes Res Clin Pract 34: 7-11, 1996.
25. Kido Y, Nakae J, Hribal ML, Xuan S, Efstratiadis A, Accili D. Effects of mutations in the insulin-like growth factor signaling system on embryonic pancreas development and beta-cell compensation to insulin resistance. J Biol Chem 277: 36740-36747, 2002.
26. Kulkarni RN, Holzenberger M, Shih DQ, Ozcan U, Stoffel M, Magnuson MA, Kahn CR. beta-cell-specific deletion of the Igf1 receptor leads to hyperinsulinemia and glucose intolerance but does not alter beta-cell mass. Nat Genet 31: 111-115, 2002.
27. Leahy JL, Vandekerkhove KM. Insulin-like growth factor-I at physiological concentrations is a potent inhibitor of insulin secretion. Endocrinology 126: 1593-1598, 1990.
28. Lingohr MK, Briaud I, Dickson LM, McCuaig JF, Alarcon C, Wicksteed BL, Rhodes CJ. Specific regulation of IRS-2 expression by glucose in rat primary pancreatic islet beta-cells. J Biol Chem 281: 15884-15892, 2006.
29. Liu JL. Does IGF-I stimulate pancreatic islet cell growth? Cell Biochem Biophys 48: 115-125, 2007.
30. Liu JL, Coschigano KT, Robertson K, Lipsett M, Guo Y, Kopchick JJ, Kumar U, Liu YL. Disruption of growth hormone receptor gene causes diminished pancreatic islet size and increased insulin sensitivity in mice. Am J Physiol Endocrinol Metab 287: E405-E413, 2004.
31. Lu Y, Herrera PL, Guo Y, Sun D, Tang Z, LeRoith D, Liu JL. Pancreatic-specific inactivation of IGF-I gene causes enlarged pancreatic islets and significant resistance to diabetes. Diabetes 53: 3131-3141, 2004.
32. Lu Y, Ponton A, Okamoto H, Takasawa S, Herrera PL, Liu JL. Activation of the Reg family genes by pancreatic-specific IGF-I gene deficiency and after streptozotocin-induced diabetes in mouse pancreas. Am J Physiol Endocrinol Metab 291: E50-E58, 2006.
33. Martinez SC, Cras-Meneur C, Bernal-Mizrachi E, Permutt MA. Glucose regulates Foxo1 through insulin receptor signaling in the pancreatic islet beta-cell. Diabetes 55: 1581-1591, 2006.
34. Mathews LS, Hammer RE, Behringer RR, D'Ercole AJ, Bell GI, Brinster RL, Palmiter RD. Growth enhancement of transgenic mice expressing human insulin-like growth factor I. Endocrinology 123: 2827-2833, 1988.
35. Mellado-Gil JM, Aguilar-Diosdado M. High glucose potentiates cytokine- and streptozotocin-induced apoptosis of rat islet cells: effect on apoptosis-related genes. J Endocrinol 183: 155-162, 2004.
36. Morgan NG, Cable HC, Newcombe NR, Williams GT. Treatment of cultured pancreatic B-cells with streptozotocin induces cell death by apoptosis. Biosci Rep 14: 243-250, 1994.
37. Moses A, Young S, Morrow L, O'Brien M, Clemmons D. Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes. Diabetes 45: 91-100, 1996.
38. O'Brien BA, Harmon BV, Cameron DP, Allan DJ. Beta-cell apoptosis is responsible for the development of IDDM in the multiple low-dose streptozotocin model. J Pathol 178: 176-181, 1996.
39. Ohneda K, Ulshen MH, Fuller CR, D'Ercole AJ, Lund PK. Enhanced growth of small bowel in transgenic mice expressing human insulin-like growth factor I. Gastroenterology 112: 444-454, 1997.
40. Okada T, Liew CW, Hu J, Hinault C, Michael MD, Krutzfeldt J, Yin C, Holzenberger M, Stoffel M, Kulkarni RN. Insulin receptors in beta-cells are critical for islet compensatory growth response to insulin resistance. Proc Natl Acad Sci USA 104: 8977-8982, 2007.
41. Pennisi P, Gavrilova O, Setser-Portas J, Jou W, Santopietro S, Clemmons D, Yakar S, LeRoith D. Recombinant human insulin-like growth factor-I treatment inhibits gluconeogenesis in a transgenic mouse model of type 2 diabetes mellitus. Endocrinology 147: 2619-2630, 2006.
42. Quaife CJ, Mathews LS, Pinkert CA, Hammer RE, Brinster RL, Palmiter RD. Histopathology associated with elevated levels of growth hormone and insulin-like growth factor I in transgenic mice. Endocrinology 124: 40-48, 1989.
43. Saukkonen T, Amin R, Williams RM, Fox C, Yuen KC, White MA, Umpleby AM, Acerini CL, Dunger DB. Dose-dependent effects of recombinant human insulin-like growth factor (IGF)-I/IGF binding protein-3 complex on overnight growth hormone secretion and insulin sensitivity in type 1 diabetes. J Clin Endocrinol Metab 89: 4634-4641, 2004.
44. Saukkonen T, Shojaee-Moradie F, Williams RM, Amin R, Yuen KC, Watts A, Acerini CL, Umpleby AM, Dunger DB. Effects of recombinant human IGF-I/IGF-binding protein-3 complex on glucose and glycerol metabolism in Type 1 diabetes. Diabetes 55: 2365-2370, 2006.
45. Scheiwiller E, Guler HP, Merryweather J, Scandella C, Maerki W, Zapf J, Froesch ER. Growth restoration of insulin-deficient diabetic rats by recombinant human insulin-like growth factor I. Nature 323: 169-171, 1986.
46. Shapiro ET, Bell GI, Polonsky KS, Rubenstein AH, Kew MC, Tager HS. Tumor hypoglycemia: relationship to high molecular weight insulin-like growth factor-II. J Clin Invest 85: 1672-1679, 1990.
47. Sieradzki J, Fleck H, Chatterjee AK, Schatz H. Stimulatory effect of insulin-like growth factor-I on [3H]thymidine incorporation, DNA content and insulin biosynthesis and secretion of isolated pancreatic rat islets. J Endocrinol 117: 59-62, 1988.
48. Simpson HL, Jackson NC, Shojaee-Moradie F, Jones RH, Russell-Jones DL, Sonksen PH, Dunger DB, Umpleby AM. Insulin-like growth factor I has a direct effect on glucose and protein metabolism, but no effect on lipid metabolism in type 1 diabetes. J Clin Endocrinol Metab 89: 425-432, 2004.
49. Tera M, Long SY, Wartschow LM, Rankin MW, Kushner JA. Very slow turnover of beta cells in aged adult mice. Diabetes 54: 2557-2567, 2005.
50. Tomas FM, Knowles SE, Chandler CS, Francis GL, Owens PC, Ballard FJ. Anabolic effects of insulin-like growth factor-I (IGF-I) and an IGF-I variant in normal female rats. J Endocrinol 137: 413-421, 1993.
51. Tomas FM, Knowles SE, Owens PC, Read LC, Chandler CS, Gargosky SE, Ballard FJ. Increased weight gain, nitrogen retention and muscle protein synthesis following treatment of diabetic rats with insulin-like growth factor (IGF)-I and des(1-3)IGF-I. Biochem J 276: 547-554, 1991.
52. Tomita T, Matsubara O. Immunocytochemical localization of metallothionein in human pancreatic islets. Pancreas 20: 21-24, 2000.
53. Ueki K, Okada T, Hu J, Liew CW, Assmann A, Dahlgren GM, Peters JL, Shackman JG, Zhang M, Artner I, Satin LS, Stein R, Holzenberger M, Kennedy RT, Kahn CR, Kulkarni RN. Total insulin and IGF-I resistance in pancreatic beta cells causes overt diabetes. Nat Genet 38: 583-588, 2006.
54. White MF. IRS proteins and the common path to diabetes. Am J Physiol Endocrinol Metab 283: E413-E422, 2002.
55. Withers DJ, Burks DJ, Towery HH, Altamuro SL, Flint CL, White MF. Irs-2 coordinates Igf-1 receptor-mediated beta-cell development and peripheral insulin signalling. Nat Genet 23: 32-40, 1999.
56. Withers DJ, Gutierrez JS, Towery H, Burks DJ, Ren JM, Previs S, Zhang Y, Bernal D, Pons S, Shulman GI, Bonner-Weir S, White MF. Disruption of IRS-2 causes type 2 diabetes in mice. Nature 391: 900-904, 1998.
57. Xuan S, Kitamura T, Nakae J, Politi K, Kido Y, Fisher PE, Morroni M, Cinti S, White MF, Herrera PL, Accili D, Efstratiadis A. Defective insulin secretion in pancreatic beta cells lacking type 1 IGF receptor. J Clin Invest 110: 1011-1019, 2002.
58. Yakar S, Liu JL, Fernandez AM, Wu Y, Schally AV, Frystyk J, Chernausek SD, Mejia W, Le Roith D. Liver-specific IGF-1 gene deletion leads to muscle insulin insensitivity. Diabetes 50: 1110-1118, 2001.
59. Yang Q, Yamagata K, Fukui K, Cao Y, Nammo T, Iwahashi H, Wang H, Matsumura I, Hanafusa T, Bucala R, Wollheim CB, Miyagawa J, Matsuzawa Y. Hepatocyte nuclear factor-1alpha modulates pancreatic beta-cell growth by regulating the expression of insulin-like growth factor-1 in INS-1 cells. Diabetes 51: 1785-1792, 2002.
60. Ye P, Carson J, D'Ercole AJ. In vivo actions of insulin-like growth factor-I (IGF-I) on brain myelination: studies of IGF-I and IGF binding protein-1 (IGFBP-1) transgenic mice. J Neurosci 15: 7344-7356, 1995.
61. Zapf J, Hauri C, Waldvogel M, Futo E, Hasler H, Binz K, Guler HP, Schmid C, Froesch ER. Recombinant human insulin-like growth factor I induces its own specific carrier protein in hypophysectomized and diabetic rats. Proc Natl Acad Sci USA 86: 3813-3817, 1989.
62. Zhao AZ, Zhao H, Teague J, Fujimoto W, Beavo JA. Attenuation of insulin secretion by insulin-like growth factor 1 is mediated through activation of phosphodiesterase 3B. Proc Natl Acad Sci USA 94: 3223-3228, 1997.